IMV Reports Positive Data for Covid-19 Vaccine Candidate
IMV Reports Positive Data for Covid-19 Vaccine Candidate
DJ IMV Reports Positive Data for Covid-19 Vaccine Candidate
By Chris Wack
IMV Inc. said Monday it is encouraged by data generated so far for its vaccine candidate, DPX-Covid-19, for the prevention of Covid-19 infection.
The biopharmaceutical company said it has successfully completed preclinical safety and good laboratory practice, or GLP, toxicology studies, as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
IMV said it is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in the first quarter of 2021 on its revised clinical plan.
None of the recent mutations reported in U.K. or in Denmark are in the areas of the four selected peptides in DPX-Covid-19. By targeting areas less prone to mutations, DPX-Covid-19 has potential to offer protection against a broader range of circulating variants, the company said.
IMV said the completed safety studies confirmed a favorable safety profile and showed potential for long-term protection with antibody titers maintained throughout the duration of studies.
The company also said it has entered into a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-Covid-19 in India and Europe with the anticipated capacity to produce several hundred million doses.
IMV shares were up 30% to $3.94 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 28, 2020 07:27 ET (12:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
DJ IMV Reports Positive Data for Covid-19 Vaccine Candidate
DJ IMV报告新冠肺炎候选疫苗的阳性数据
By Chris Wack
克里斯·瓦克(Chris Wack)著
IMV Inc. said Monday it is encouraged by data generated so far for its vaccine candidate, DPX-Covid-19, for the prevention of Covid-19 infection.
IMV公司周一表示，到目前为止为其候选疫苗DPX-新冠肺炎提供的预防新冠肺炎感染的数据令他们感到鼓舞。
The biopharmaceutical company said it has successfully completed preclinical safety and good laboratory practice, or GLP, toxicology studies, as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.
这家生物制药公司表示，它已经成功完成了临床前安全性和良好的实验室实践，即GLP，毒理学研究，以及免疫原性和挑战性研究，证实了良好的安全性概况和长期抗体滴度和对SARS-CoV-2的保护潜力。
IMV said it is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in the first quarter of 2021 on its revised clinical plan.
IMV表示，它正计划进行补充性临床前研究，包括测试新的变种，并将在2021年第一季度提供修订后的临床计划的最新情况。
None of the recent mutations reported in U.K. or in Denmark are in the areas of the four selected peptides in DPX-Covid-19. By targeting areas less prone to mutations, DPX-Covid-19 has potential to offer protection against a broader range of circulating variants, the company said.
最近在英国或丹麦报道的突变都不在DPX-新冠肺炎中选定的四个肽的区域。该公司表示，通过瞄准不太容易发生突变的地区，DPX-新冠肺炎有可能提供保护，抵御更广泛的流通变体。
IMV said the completed safety studies confirmed a favorable safety profile and showed potential for long-term protection with antibody titers maintained throughout the duration of studies.
IMV说，完成的安全性研究证实了有利的安全性概况，并显示出在整个研究期间保持抗体效价的长期保护潜力。
The company also said it has entered into a collaboration with a global manufacturing partner and initiated transfer and scale-up activities of DPX-Covid-19 in India and Europe with the anticipated capacity to produce several hundred million doses.
该公司还表示，它已经与一家全球制造合作伙伴建立了合作关系，并启动了DPX-新冠肺炎在印度和欧洲的转移和扩大活动，预计将有数亿剂的生产能力。
IMV shares were up 30% to $3.94 in premarket trading.
IMV股价在盘前交易中上涨30%，至3.94美元。
Write to Chris Wack at chris.wack@wsj.com
写信给克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道琼通讯社
December 28, 2020 07:27 ET (12:27 GMT)
2020年12月28日东部时间07：27(格林尼治标准时间12：27)
Copyright (c) 2020 Dow Jones & Company, Inc.
版权所有(C)2020道琼斯公司。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧